ClinicalTrials.gg
CompletedNCT07337291Updated Jan 13, 2026

Double Stent for Biliary Stones in Cirrhotic Patients

An interventional study of Single 10 Fr Plastic Biliary Stent and Two 10 Fr Plastic Biliary Stent in Liver Circulation, Choledocholithiasis and Stent, sponsored by National Liver Institute, Egypt. Completed at 1 site in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by National Liver Institute, Egypt · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years after the study started (first participant enrolled Jan 2022, registered Jan 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This prospective, single-center, interventional study enrolled 400 cirrhotic patients with large or complex common bile duct (CBD) stones that could not be removed during an initial Endoscopic Retrograde Cholangiopancreatography (ERCP). The study compared four different plastic biliary stenting strategies (single 10 Fr, double 10 Fr, single 11.5 Fr, and single 10 Fr pigtail stents) to determine the optimal approach for facilitating successful stone clearance in a subsequent ERCP and minimizing complications in this high-risk patient population.

Read the detailed description

Background and Rationale: The primary treatment for choledocholithiasis is Endoscopic Retrograde Cholangiopancreatography (ERCP) with sphincterotomy. However, complete stone clearance fails in 10-15% of cases involving complex choledochal stones (e.g., larger than 15 mm and/or more than 3 stones), often necessitating recurrent ERCP procedures. This challenge is compounded in high-risk patients, such as the elderly or those with substantial comorbidities, who cannot tolerate prolonged procedures. Failure to extract stones can also be attributed to anatomical factors like complex stones, periampullary diverticula, or ductal anomalies. While alternative methods like ESWL or lithotripsy exist, they are not universally available. Temporary plastic biliary stent placement is a safe and effective alternative, providing biliary drainage and acting as a bridge to subsequent stone removal. Short-term stenting can reduce stone size and improve the success rate of later extraction.

The aim of this work is to evaluate the role and efficiency of different types or different numbers of plastic stent application in the treatment of non-retrievable large biliary stones in liver cirrhosis.

Study Design and Setting: This is a prospective, single-center, interventional study conducted at the National Liver Institute, Menoufia University, Egypt, between January 2022 and January 2025. The study was authorized by the Institutional Ethics Committee (Approval No.: 00787/2025). A total of 400 cirrhotic patients with calculous biliary obstruction were included. Study Population and Eligibility: Participants were adults with established liver cirrhosis classified as high-risk due to moderate to severe liver disease and/or substantial comorbidities, who could not safely tolerate extended endoscopic or surgical intervention. They all presented with large or complex Common Bile Duct (CBD) stones that could not be removed during the initial ERCP. All enrolled subjects were clinically stable and provided signed informed consent. Exclusion criteria included non-cirrhotic patients, non-calculous causes of biliary obstruction (e.g., portal biliopathy, malignant obstruction), acute suppurative cholangitis, ERCP contraindications, or inability to complete the scheduled 12-month follow-up.

Interventions and Study Groups: Enrolled individuals were allocated into four parallel groups based on the type and size of the plastic biliary stent used during ERCP: Group 1 (Single plastic stent, 10 cm × 10 Fr), Group 2 (Double plastic stents, each 10 cm × 10 Fr), Group 3 (Single plastic stent, 10 cm × 11.5 Fr), and Group 4 (Single pigtail stent, 10 cm × 10 Fr). ERCP Procedure: All ERCPs were performed by expert hepatobiliary endoscopists under general anesthesia using a standard side-viewing duodenoscope. Following selective CBD cannulation, stone extraction was attempted. When complete clearance was not achievable, the appropriate plastic stent(s) were placed over a guidewire, with or without a previous sphincterotomy. Prolonged procedures, advanced lithotripsy techniques, and chemical stone dissolution were deliberately avoided due to the high-risk nature of the study population. Data Collection and Follow-up: Thorough clinical and demographic data were systematically documented. Baseline laboratory investigations included renal function tests, CBC, CRP, pancreatic enzymes, and a full liver biochemical profile. Imaging (ultrasonography and MRCP) was used to characterize stone size, number, and biliary anatomy. Patients were observed for a minimum of 24 hours post-procedure. Follow-up assessments were scheduled at 1 month and subsequently at 3-6 month intervals or on demand. The total monitoring period was 12 months, with the final assessment completed by January 2026. Follow-up involved clinical assessment, laboratory tests, and abdominal radiographs to assess biliary drainage and stent patency. Patients with signs of stent malfunction underwent repeat ERCP.

Outcome Measures: The main outcomes were stent patency and successful stone clearance at the second ERCP. Secondary objectives included reduction in stone size, all-cause mortality throughout the follow-up period, and procedure-related complications (stent migration, cholangitis, post-ERCP pancreatitis, and hemorrhage).

Statistical Analysis: Statistical analysis will be performed using IBM SPSS Statistics (version 22). Comparisons among groups will be completed using the chi-square (χ²) test or Monte Carlo correction for categorical variables, one-way ANOVA for normally distributed continuous variables, and the Kruskal-Wallis test for non-normally distributed variables. A p-value ≤ 0.05 is considered statistically significant.

02

Conditions studied

  • Liver Circulation
  • Choledocholithiasis
  • Stent

Keywords

  • ERCP
  • Biliary Stent
  • Double Stent
  • Liver Cirrhosis
  • Non-Retrievable Stones
  • High-Risk Patients
03

In context

Choledocholithiasis

109 studies on the registry are indexed under Choledocholithiasis; 24 are open to participants now.

This study's enrollment of 400 is above the median of 100 across 76 interventional studies indexed under Choledocholithiasis.

Browse Choledocholithiasis studies →

Lead sponsor

National Liver Institute, Egypt is the lead sponsor of 18 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults with established liver cirrhosis.
  2. Presence of large or complex common bile duct (CBD) stones that were non-retrievable during the initial ERCP.
  3. Classified as high-risk due to moderate to severe liver disease and/or substantial comorbidities, making them unable to safely tolerate extended endoscopic procedures or surgical intervention.
  4. Clinically stable and capable of undergoing the scheduled diagnostic and therapeutic procedures.
  5. Provided signed before enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Non-cirrhotic patients.
  2. Patients with non-calculous causes of biliary obstruction (e.g., portal biliopathy, benign biliary strictures, or malignant biliary obstruction).
  3. Acute suppurative cholangitis.
  4. to ERCP.
  5. Inability to complete the scheduled 12-month follow-up time.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (actual)

Study arms

  • Experimental
    Single 10 Fr Plastic Stent

    Placement of a single 10 French (Fr), 10 cm plastic biliary stent.

    Device: Single 10 Fr Plastic Biliary Stent

  • Experimental
    Double 10 Fr Plastic Stents

    Placement of two 10 French (Fr), 10 cm plastic biliary stents side-by-side.

    Device: Two 10 Fr Plastic Biliary Stent

  • Experimental
    Single 11.5 Fr Plastic Stent

    Placement of a single 11.5 French (Fr), 10 cm plastic biliary stent.

    Device: Single 11.5 Fr Plastic Biliary Stent

  • Experimental
    Single 10 Fr Pigtail Stent

    Placement of a single 10 French (Fr), 10 cm pigtail plastic biliary stent.

    Device: Single 10 Fr Pigtail Stent

Interventions

  • DeviceSingle 10 Fr Plastic Biliary Stent

    Single 10 Fr, 10 cm plastic stent placed endoscopically.

  • DeviceTwo 10 Fr Plastic Biliary Stent

    Two 10 Fr, 10 cm plastic stents placed endoscopically.

  • DeviceSingle 11.5 Fr Plastic Biliary Stent

    Single 11.5 Fr, 10 cm plastic stent placed endoscopically.

  • DeviceSingle 10 Fr Pigtail Stent

    Single 10 Fr, 10 cm pigtail plastic stent placed endoscopically.

06

What researchers measure

Primary outcomes

  1. Stent Patency

    Time from stent placement until clinical or biochemical evidence of stent occlusion (e.g., cholangitis, elevated liver enzymes, or imaging findings).

    Time frame: 6 months

  2. Successful Stone Clearance in Second ERCP

    The proportion of patients in each group achieving complete clearance of common bile duct stones during the second, planned ERCP session.

    Time frame: 6 months

Secondary outcomes

  1. Incidence of Procedure-Related Complications

    Incidence of adverse events, including stent migration, cholangitis, post-ERCP pancreatitis, and hemorrhage.

    Time frame: From stenting until 30 days after the second ERCP.

  2. Reduction in Stone Size

    Mean reduction in the largest stone diameter, measured by cholangiography or MRCP, between initial stenting and the second ERCP.

    Time frame: 6 months

  3. All-Cause Mortality

    The number of deaths from any cause during the study follow-up period

    Time frame: 12 months

07

Study locations

1 site
  • National Liver Institute, Menoufia University, Egypt.
    Shibīn al Kawm, Menoufia 32511, Egypt
08

References and documents

Publications

  • Lee TH, Han JH, Kim HJ, Park SM, Park SH, Kim SJ. Is the addition of choleretic agents in multiple double-pigtail biliary stents effective for difficult common bile duct stones in elderly patients? A prospective, multicenter study. Gastrointest Endosc. 2011 Jul;74(1):96-102. doi: 10.1016/j.gie.2011.03.005. Epub 2011 Apr 30. PubMed 21531412 ↗
  • Horiuchi A, Nakayama Y, Kajiyama M, Kato N, Kamijima T, Graham DY, Tanaka N. Biliary stenting in the management of large or multiple common bile duct stones. Gastrointest Endosc. 2010 Jun;71(7):1200-1203.e2. doi: 10.1016/j.gie.2009.12.055. Epub 2010 Apr 18. PubMed 20400079 ↗
  • Binmoeller KF, Schafer TW. Endoscopic management of bile duct stones. J Clin Gastroenterol. 2001 Feb;32(2):106-18. doi: 10.1097/00004836-200102000-00004. PubMed 11205644 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Jan 2025, 36 months.

Of 41 non-industry interventional studies with no phase under Choledocholithiasis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 36 months is above that.

Counting every sponsor, half of 43 studies reached it within 21 months; a quarter within 12 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 1, 2026
First posted
Jan 13, 2026
StartActual
Jan 1, 2022
Primary completionActual
Jan 1, 2025
CompletionActual
Jan 1, 2026
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07337291
Lead sponsor
National Liver Institute, Egypt
Responsible party
Sponsor
First posted
Jan 13, 2026
Start date
Jan 1, 2022
Primary completion
Jan 1, 2025
Completion
Jan 1, 2026
Last update
Jan 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion